An Assistant Model for IRD Care Needs: A Randomized Control Trial

Shanghai Jiao Tong University

Status

Completed

Conditions

Inherited Retinal Diseases

Treatments

Other: without FM-IRDs

Other: FM-IRDs assisted

Study type

Interventional

Funder types

Other

Identifiers

NCT06839170

2022YFC2502800 (Other Grant/Funding Number)

EyeFM-IRDs

Details and patient eligibility

About

we present FM-IRD（also designated as Retina4IRD）, the first foundation model-based AI system specifically designed for genotype diagnosis of IRD by emulating clinician decision-making reasoning process. Retina4IRD is capable of processing multimodal input including color fundus photography (CFP), optical coherence tomography (OCT), and descriptive medical metadata. Trained and validated on genetically confirmed cases from centers across China, South Korea, and Poland, the system generates a ranked list of candidate pathogenic genetic variants. Retina4IRD also can generated attention heatmaps to enhance decision-making interpretability. To validate its clinical impact, we conducted a prospective multicenter RCT involving 295 participants, rigorously assessing Retina4IRD's diagnostic accuracy and real-world utility. This will improve the standardized diagnosis of IRD diseases, effectively transforming the traditional time-consuming and resource-intensive diagnostic pathway into an efficient intelligent workflow

Full description

A randomized, controlled validation trial was conducted to evaluate the effectiveness of Retina4IRD (also designated as FM-IRD) in clinical settings. This trail was conducted at seven centers in China with large outpatient IRDs care .

Participants were recruited from the outpatient of IRD clinics of the participating centers, or through referrals from collaborating retinal specialists. Given that genetic testing results were unavailable at enrollment, and to prioritize the model's ability to identify patients with actionable therapeutic targets, genotypes of our randomized controlled trial were categorized into 17 classes, including mutations with available gene therapies or ongoing clinical trials. All participants provided written informed consent before enrolment assessments. All participants subsequently underwent WES testing to confirm the causative genetic mutations, which served as the gold standard for IRD gene mutation diagnosis.

Enrollment

300 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Presenting with clinical features suggestive of suspected IRD based on the initial assessment by the physician

Exclusion criteria

Refusal to undergo WES genetic testing.
Screening for a history of intraocular surgery in both eyes within the past 6 months;
Subjects with severe systemic diseases, intellectual developmental disorders, psychiatric illnesses, etc.
Patient data that the investigator deems necessary to exclude.